Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2005-04-26
2005-04-26
Scheiner, Laurie (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S199100, C424S093600, C435S235100, C435S236000, C435S069300
Reexamination Certificate
active
06884414
ABSTRACT:
The present invention relates to the engineering of recombinant influenza viruses that express tumor-associated antigens. Expression of tumor-associated antigens by these viruses can be achieved by engineering specific epitopes into influenza virus proteins, or by engineering viral genes that encode a viral protein and the specific antigen as independent polypeptides. Tumor-bearing patients can be immunized with the recombinant influenza viruses alone, or in combination with another treatment, to induce an immune response that leads to tumor reduction. The recombinant viruses can also be used to vaccinate high risk tumor-free patients to prevent tumor formation in vivo.
REFERENCES:
patent: 4690915 (1987-09-01), Rosenberg et al.
patent: 5081029 (1992-01-01), Zarling et al.
patent: 5166057 (1992-11-01), Palese et al.
patent: 5578473 (1996-11-01), Palese et al.
patent: 5854037 (1998-12-01), Palese et al.
patent: WO 9321306 (1993-10-01), None
Akagi et al. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. J Immunother. Jan. 1997;20(1):38-47.
Durrant LG. Cancer vaccines. Anticancer Drugs. Sep. 1997;8(8):727-33. Review.
Itoh et al. Development of cancer vaccine by tumor rejection antigens.Int Rev Immunol. 1997;14(2-3):153-71. Review.
Kawakami et al. Human melanoma antigens recognized by T lymphocytes. Kieo J Med. Jun. 1996;45(2):100-8. Review.
Kawakami Y and Rosenberg SA., T-cell recognition of self peptides as tumor rejection antigens. Immunol Res. 1996;15(3):179-90. Review.
Krainer et al. Tissue expression and serum levels of HER-2
eu in patients with breast cancer. Oncology. Nov.-Dec. 1997;54(6):475-81.
Maeurer et al. New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines, Melanoma Res. Feb. 1996;6(1):11-24, Review.
McCabe et al. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. Cancer Res. Apr. 15, 1995;55(8):1741-7.
Osanto S. Vaccine Trails for the Clinician: Prospects for Tumor Antigens. Oncologist. 1997;2(5):284-299.
Rosenberg et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst. Dec. 16, 1998;90(24):1894-900.
Zhai et al. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother. Jan. 1997;20(1):15-25.
Zhai et al. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J Immunol. Jan. 15, 1996;156(2):700-10.
Ansardi et al., 1994, “Characterization of poliovirus replicons encoding carcinoembryonic antigen”, Cancer Res. 54:6359-6364.
Chen et al., 1996, “Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen”, J. Immunol. 156:224-231.
Conry et al., 1995, “A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity”, Gene Ther. 2:59-65.
Enami and Palese, 1991, “High-efficiency formation of influenza virus transfectants”, J. Virol. 65:2711-2713.
Garcia-Sastre et al., 1994, “Use of a mammalian internal ribosomal entry site element for expression of a foreign protein by a transfectant influenza virus”, J. Virol. 68:6254-6261.
Garcia-Sastre and Palese, 1993, “Genetic manipulation of negative-strand RNA virus genomes”, Annu. Rev. Microbiol. 47:765-790.
Greenberg, 1991, “Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells”, Adv. Immunol. 49:281-355.
Hodge et al., 1995, “A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate”, Int. J. Cancer 63:231-237.
Irvine et al., 1996, “Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases”, J. Immunol. 156:238-245.
Irvine et al., 1995, “Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL”, J. Immunol. 154:4651-4657.
Johanning et al., 1995, “A sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo”, Nucl. Acids Res. 23:1495-1501.
McCab et al., 1995, “Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses”, Cancer Res. 55:1741-1747.
Moss, 1996, “Poxviridae: the viruses and their replication”, in:Fields Virology, Fields et al., eds., Lippincott-Raven, Philadelphia, pp. 2637-2671.
Murata et al., 1996, “Characterization of in vivo primary and secondary CD8+T cell responses induced by recombinant influenza and vaccinia viruses”, Cell Immunol. 173:96-107.
Muster et al., 1995, “Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus”, J. Virol. 69:6678-6686.
Muster et al., 1994, “Cross-neutralizing activty against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS”, J. Virol. 68:4031-4034.
Plotkin et al., 1995, “The safety and use of canarypox vectored vaccines”, Dev. Biol. Stand. 84:165-170.
Randrianarison-Jewtoukoff and Perricaudet, 1995, “Recombinant adenoviruses as vaccines”, Biologicals 23:145-157.
Rao et al., 1996, “IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression”, J. Immunol. 156:3357-3365.
Restifo, 1996, “The new vaccines: building viruses that elicit antitumor immunity”, Curr. Opin. Immunol. 8:658-663.
Restifo et al., 1995, “Antigen processing in vivo and the elicitation of primary CTL responses”, J. Immunol. 154:4414-4422.
Rodrigues et al., 1994, “Influenza and vaccinia viruses expressing malaria CD8+T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity”, J. Immunol. 153:4636-4648.
Rosenberg et al., 1994, “Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2”, J. Natl. Cancer Inst. 86:1159-1166.
Wang et al., 1995, “Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen”, J. Immunol. 154:4685-4692.
Garcia-Sastre Adolfo
Palese Peter
Restifo Nicholas F.
Jones Day
Mount Sinai School of Medicine of New York University
Scheiner Laurie
The United State of America as represented by the Department of
LandOfFree
Recombinant influenza viruses expressing tumor-associated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant influenza viruses expressing tumor-associated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant influenza viruses expressing tumor-associated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3411694